Summary

Overview
The global invasive fungal infection treatment market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Invasive fungal infection (IFI) is one of the most common nosocomial infections and may result in invasive diseases in patients with various underlying diseases or other host factors. Invasive Fungal Diseases (IFD) are frequent infectious complications of hematopoietic stem cell transplantation.
Invasive Fungal Infections (IFIs) arise when fungi invade the body's deep tissues or organs. Invasive fungal infections have the potential to be fatal, in contrast to superficial fungal infections, which only affect the skin, hair, or nails. Directed antifungal treatment is used for patients with documented fungal disease.
Market Dynamics: Drivers & Restraints
Rising drug developments
Increasing drug developments against invasive fungal infections are expected to drive market growth during the forecast period. A large number of individuals are being affected by fungal infections and need effective drugs. Rising drug development increases the demand for new products and also serves the patients who are in need.
Several pharmaceutical companies are introducing a wide variety of treatment options that could treat invasive fungal infections. For instance, in September 2023, BDR Pharmaceutical launched the generic antifungal drug Zisavel (isavuconazole) for the treatment of infections like invasive aspergillosis and mucormycosis.
Additionally, on 17 Apr 2023, Cidara Therapeutics and Melinta Therapeutics received U.S. FDA approval for Rezzayo (rezafungin for injection). This new medication is for the treatment and prevention of candidemia and invasive candidiasis in adults who have limited or no alternative treatment options.
Also, on January 29, 2024, Cidara Therapeutics, Inc. received the United Kingdom (U.K.) Medicines and Healthcare Products Regulatory Agency (MHRA) approval for REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults. Thus, the above factors are expected to drive market growth during the forecast period.
Consequences of immunosuppressive treatment
Antifungal activity of some immunosuppressive agents can lead to harmful microbiota changes and the selection of environmental species or isolates resistant to these drugs. Additionally, drug-drug interactions and genetic determinants of the patient might lead to suboptimal levels of drug accumulation and toxicity. Thus, the above factors are expected to hamper the market growth.
For more details on this report – Request for Sample
Segment Analysis
The global invasive fungal infection treatment market is segmented based on disease type, drug type, distribution channel, and region.
The triazoles segment is expected to dominate the market share
The triazoles segment is expected to dominate the market growth during the forecast period, this is due to the effectiveness of these drugs over invasive fungal infections. Triazoles perform effectively against many of the fungi that cause IFIs, such as Aspergillus, Candida, and some molds. Because of this, they provide a flexible first treatment option while medical professionals determine the exact type of fungus. Triazoles often have fewer adverse effects and a better safety profile than certain other antifungal groups.
For individuals with impaired immune systems who might already be coping with other medical conditions, this is crucial. Triazoles come in several forms, such as oral suspensions, intravenous solutions, tablets, and capsules. This makes it possible to use various treatment strategies based on the patient's state and the infection's severity. Triazoles have been used to treat IFIs for a long time. Thus, the above factors are expected to drive the market growth.
The growing number of alternative products is also expected to drive the segment growth. Pharmaceutical companies are increasingly providing a variety of triazole drugs which could help in the expansion of the segment growth.
For instance, in July 2021, Cadila Pharmaceuticals launched a new triazole antifungal drug Posaconazole, which is effective against a wide range of invasive fungal diseases. The drug has also been recommended as a second-line treatment for Mucormycosis or black fungus as it is commonly known. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the invasive fungal infection treatment market share
North America is expected to hold a dominant position in the invasive fungal infection treatment market due to the high prevalence of invasive fungal infection, and rising public awareness of invasive fungal diseases are some of the factors expected to boost the market in the forecast period.
For instance, according to the Centers for Disease Control & Prevention in 2024, it stated that candidemia is one of the most common bloodstream infections in the United States. An estimated 25,000 cases of candidemia occur in the United States each year.
Additionally, people get histoplasmosis in certain areas in the United States, particularly around the Mississippi and Ohio River valleys. Around 60-90% of people living in that area are exposed to Histoplasma in their lifetime. The increasing prevalence of invasive fungal infections in the region is expected to increase the demand for the drugs available. Thus, the above factors are expected to hold the region in the dominant position during the forecast period.
Market Segmentation
By Disease Type
● Candidemia and Invasive Candidiasis
● Intra-abdominal Candidiasis
● Cryptococcal Meningitis
● Esophageal Candidiasis
● Histoplasmosis Acute Pulmonary
● Invasive Aspergillosis
● Invasive Rhinosinusitis
● Mucormycosis
● Others
By Drug Type
● Polyenes
o Amphotericin B deoxycholate
o Lipid formulation amphotericin B.
o Others
● Triazoles
o Fluconazole
o Itraconazole
o Posaconazole
o Voriconazole
o Others
● Echinocandins
o Anidulafungin
o Caspofungin
o Micafungin
o Others
● Flucytosine
● Others
By Distribution Channel
● Hospital Pharmacies
● Retail Pharmacies
● Others
By Region
● North America
o U.S.
o Canada
o Mexico
● Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
● South America
o Brazil
o Argentina
o Rest of South America
● Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
● Middle East and Africa
Competitive Landscape
The major global players in the market include Merck & Co., Inc., Fresenius Kabi AG, Cidara Therapeutics Inc., Xellia Pharmaceuticals, Aark Pharmaceuticals., Intelicure Lifesciences, Taj Life Sciences Pvt Ltd, Angle Bio Pharma, Cadila Pharmaceuticals Limited and Stanex Drugs & Chemicals Pvt. Ltd. among others.
Key Developments
● In January 2024, Fresenius Kabi introduced Posaconazole Injection, a generic substitute for Noxafil, for use in treating or preventing serious fungal infections in adults and children. It’s also used to prevent invasive aspergillus and candida infections in patients who are severely immunocompromised, including adults and pediatric patients age 2 or older.
● On March 6, 2024, the Food and Drug Administration approved the sale of the anti-fungal drug, Cresemba, for use against invasive aspergillosis and invasive mucormycosis.
Why Purchase the Report?
● To visualize the global invasive fungal infection treatment market segmentation based on disease type, drug type, distribution channel, and region as well as understand key commercial assets and players.
● Identify commercial opportunities by analyzing trends and co-development.
● Excel data sheet with numerous data points of invasive fungal infection treatment market-level with all segments.
● PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
● Product mapping available as Excel consisting of key products of all the major players.
The global invasive fungal infection treatment market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising drug developments
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Consequences of immunosuppressive treatment
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Disease Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Candidaemia and Invasive Candidiasis*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Intra-abdominal Candidiasis
6.4. Cryptococcal Meningitis
6.5. Esophageal Candidiasis
6.6. Histoplasmosis Acute Pulmonary
6.7. Invasive Aspergillosis
6.8. Invasive Rhinosinusitis
6.9. Mucormycosis
6.10. Others
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Polyenes*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Amphotericin B deoxycholate
7.2.4. Lipid formulation amphotericin B.
7.2.5. Others
7.3. Triazoles
7.3.1. Fluconazole
7.3.2. Itraconazole
7.3.3. Posaconazole
7.3.4. Voriconazole
7.3.5. Others
7.4. Echinocandins
7.4.1. Anidulafungin
7.4.2. Caspofungin
7.4.3. Micafungin
7.4.4. Others
7.5. Flucytosine
7.6. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.1.2. Market Attractiveness Index, By Disease Type
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.3.1. U.S.
9.2.3.2. Canada
9.2.3.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.4.1. Germany
9.3.4.2. UK
9.3.4.3. France
9.3.4.4. Italy
9.3.4.5. Spain
9.3.4.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.4.1. Brazil
9.4.4.2. Argentina
9.4.4.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.4.1. China
9.5.4.2. India
9.5.4.3. Japan
9.5.4.4. South Korea
9.5.4.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Merck & Co., Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Fresenius Kabi AG
11.3. Cidara Therapeutics Inc.
11.4. Xellia Pharmaceuticals
11.5. Aark Pharmaceuticals.
11.6. Intelicure Lifesciences
11.7. Taj Life Sciences Pvt Ltd
11.8. Angle BioPharma
11.9. Cadila Pharmaceuticals Limited
11.10. Stanex Drugs & Chemicals Pvt. Ltd.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us